New Guidelines for Myocardial Ischemia Management.

Slides:



Advertisements
Similar presentations
JNC 8 Guidelines….
Advertisements

The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure
Lipid Disorders and Management in Diabetes
Canadian Diabetes Association Clinical Practice Guidelines Dyslipidemia Chapter 24 G. B. John Mancini, Robert A. Hegele, Lawrence A. Leiter.
Benefits of intensive multiple risk factor intervention.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Canadian Diabetes Association Clinical Practice Guidelines Vascular Protection in People with Diabetes Chapter 22 James A. Stone, David Fitchett, Steven.
DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.
Cardiovascular Disease in Women Module VII: Evidence-Based Guidelines.
Drugs for Hypertension

ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
Unstable Angina /Non-ST Elevation Myocardial Infarction Critical Pathway Toolkit Adapted from Dr Chris Cannon STRIVE Scientific Committee – 2008 Based.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
DR. IDOWU AKOLADE EDM DIVISION LUTH
Dr Jayachandran Thejus.  Coronary artery disease-  Block in coronary artery due to plaque or thrombus  Leads to myocardial ischemia manifested as chest.
The Science: CHD and Diabetes as Co-morbidities Kathy Reims, MD Center for Strategic Innovation 8/27/07.
Basma Y. Kentab. Aggressive comprehensive risk factor management: Improves survival, Reduces recurrent events and Reduces need for interventional procedures,
Redefining Treatment Strategies for Optimal Medical Care in CAD COURAGE and MERLIN-TIMI 36.
Blood pressure control in primary health care WORKSHOP
Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.
Benefits of adding a energetic agent to  -blockers to achieve optimal reduction of angina. Review of the main studies.
Morbidity and Mortality in Contemporary CAD Patients With Hypertension Treated With Either a Verapamil/Trandolapril or Beta-Blocker/Diuretic Strategy (INVEST):
10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
1 Current & New treatment strategies to address CV Risk.
CardioVascular Disease Prevention. CVD prevention ‘The evidence that most cardiovascular disease is preventable continues to grow.’ ‘The evidence that.
UPDATE ON MANAGEMENT OF HYPERTENSION. Classification of BLOOD PRESSURE for adults 18 yrs. Or older BP ClassificationSystolic BP, mm of hgDiastolic BP,
Ongoing Trials in Managing Myocardial Ischemia. MERLIN-TIMI 36: Study design IV/oral ranolazinePlacebo Patients with non-ST elevation ACS treated with.
VBWG PROactive: Study design Dormandy JA et al. Lancet. 2005;366: Charbonnel B et al. Diabetes Care. 2004;27: Objective: Assess the effects.
Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.
Clinical Management of Chronic Stable Angina. Anti-ischemic strategies in stable CAD Medical therapyPCICABG Initial therapy Recurrent ischemia TMREECPSCS.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Effects of Ranolazine: from Angina to Cardiac Performance Iacopo Olivotto, MD Referral Center for Cardiomyopathies Careggi University Hospital Florence,
PHARMACOTHERAPY OF HYPERTENSION Based on New Guidelines Fariborz Nikaeen; MD Interventional cardiologist 2 november 2015.
Advancing Our Understanding of RAAS Modulation in High-Risk Patients.
JNC 7 血壓分期. 血壓分期 JNC 7 : 1. 增加高血壓前期 2.Stages 2 及 3 高血壓被合併 JNC 7, 2003.
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for.
HTN & CKD 1. HTN has been reported to occur in 85-95% of patients with CKD (stages 3–5). The relationship between HTN & CKD is cyclic in nature. Uncontrolled.
Cholesterol Measurement All adults should have their blood cholesterol measured every 5 years May be in non-fasting state Fasting preferred
Date of download: 7/7/2016 From: Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American.
Ranolazine The mechanism of action of ranolazine has not been determined, but it may be related to reduction in calcium overload in ischemic myocytes.
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
Hypertension guidelines What’s all the controversy about 2015
JNC VIII Hypertension.
Drugs for Hypertension
Vanguard Phase Results for the Blood Pressure Component
Algorithm for guideline-directed medical therapy for patients with SIHD. Colors correspond to the class of recommendations in the ACCF/AHATable The.
Achieving the Clinical Potential of RAAS Blockade
WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,
Emerging Mechanisms in Glucose Metabolism
Prevalence of statin and beta-blocker use by clinical presentation
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.
Section 9: Continuum of care: Summary and timeline
Section III: Neurohormonal strategies in heart failure
Primary Hypertension Max C. Reif, M.D.
Goals & Guidelines A summary of international guidelines for CHD
Cardiovascular Disease in Women Module III: Risk Assessment Tool
Cardiovascular Disease in Women Module IX: Presentation Resources and Internet Resources This slide set was updated April 2008.
Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.
An updated general approach for achieving BP goals in people with diabetes. An updated general approach for achieving BP goals in people with diabetes.
Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.
Presentation transcript:

New Guidelines for Myocardial Ischemia Management

β-blocker (prior MI), ACEI/ARB (diabetes and/or LV dysfunction), and diuretic If β-blocker contraindicated or side effects occur, substitute a nonDHP CCB Add long-acting DHP CCB to β-blocker, ACEI/ARB, diuretic regimen if angina or BP remains uncontrolled Target BP is <130/80 mm Hg or <120/80 mm Hg if LV dysfunction is present AHA Scientific Statement: Pharmacologic treatment of hypertension in stable anginaIIIaIIbIII A B B B Rosendorff C et al. Circulation. 2007;115:

BP <120/80 mm Hg LDL-C <100 mg/dL Antiplatelet therapy β-Blocker ACEI or ARB A1C <7% Aldosterone blocker (select women) CVD prevention in high-risk women: Class I recommendations Smoking cessation Heart-healthy eating pattern Regular physical activity Weight management Mosca L et al. Circulation. 2007;115:

CVD prevention in high-risk women: Class II recommendations Consider LDL-C <70 mg/dL (very-high-risk women) HDL/non-HDL therapy Omega-3 fatty acid supplementation Depression referral and treatment Mosca L et al. Circulation. 2007;115:

Optimal patient care in stable CAD: Summary Establish aggressive treatment goals Utilize intensive, multifaceted therapy to achieve and maintain treatment goals –Lifestyle modification –Risk factor reduction –Antianginal therapy